Table of Contents

company-logo

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

PureTech Health Dividend Announcement

• PureTech Health does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on PureTech Health dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

PureTech Health Dividend History

PureTech Health Dividend Yield

PureTech Health current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing PureTech Health stock? Use our calculator to estimate your expected dividend yield:

PureTech Health Financial Ratios

P/E ratio-59.67
PEG ratio3.98
P/B ratio19.36
ROE-26.28%
Payout ratio0.00%
Current ratio3.68
Quick ratio3.64
Cash Ratio2.23

PureTech Health Dividend FAQ

Does PureTech Health stock pay dividends?
PureTech Health does not currently pay dividends to its shareholders.
Has PureTech Health ever paid a dividend?
No, PureTech Health has no a history of paying dividends to its shareholders. PureTech Health is not known for its dividend payments.
Why doesn't PureTech Health pay dividends?
There are several potential reasons why PureTech Health would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will PureTech Health ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While PureTech Health has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is PureTech Health a dividend aristocrat?
PureTech Health is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is PureTech Health a dividend king?
PureTech Health is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is PureTech Health a dividend stock?
No, PureTech Health is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy PureTech Health stocks?
To buy PureTech Health you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy PureTech Health stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.